Brought to you by 
Prexton gets €8.7mm in Series A financing co-led by Sunstone and Ysios
25 Feb 2015
Executive Summary
Prexton Therapeutics, a 2012 Merck Serono spin-off focused on Parkinson's disease, received €8.7mm ($10mm) in a Series A financing co-led by Sunstone Capital and Ysios Capital (which both contribute board members) and including returning investor MS Ventures. The money will help Prexton advance a lead metabotropic glutamate receptor 4 positive allosteric modulator (licensed from Domain Therapeutics) through Phase I for Parkinson's-related motor symptoms.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Prexton gets €8.7mm in Series A financing co-led by Sunstone and Ysios
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice